wide
report
respiratori
tract
infect
rti
signific
caus
morbid
mortal
develop
develop
nation
time
laboratori
diagnosi
proven
import
part
clinic
algorithm
ambulatori
critic
care
set
key
object
etiolog
diagnosi
rti
includ
avoid
empir
antibiot
treatment
b
allow
narrow
antibiot
treatment
c
appropri
use
antivir
drug
enabl
patient
cohort
limit
nosocomi
spread
case
hospit
e
provis
accur
epidemiolog
inform
formul
prevent
therapeut
recommend
f
gener
reduct
patient
manag
cost
past
two
decad
technolog
use
laboratori
diagnosi
rti
evolv
dramat
viru
isol
via
cell
cultur
techniqu
made
substanti
advanc
term
time
result
pathogen
coverag
assay
also
incorpor
clinic
practic
notwithstand
advanc
made
test
method
limit
led
unmet
need
diagnost
laboratori
address
new
tool
notabl
nucleic
assay
develop
detect
respiratori
virus
respiratori
virus
caus
agent
signific
number
patient
present
rti
clinician
well
serv
time
laboratori
diagnosi
either
rule
rule
virus
overlap
clinic
present
addit
avail
sensit
specif
method
respiratori
viru
detect
aid
manag
chronic
pulmonari
condit
b
medic
complic
associ
rti
final
emerg
novel
strain
respiratori
virus
notabl
respons
signific
outbreak
epidem
pandem
highlight
need
comprehens
flexibl
diagnost
algorithm
review
aim
provid
overview
advanc
made
diagnosi
rti
last
two
decad
also
discuss
specif
role
play
rvp
respiratori
viral
panel
commerci
luminex
molecular
diagnost
toronto
canada
award
us
medal
sinc
mid
varieti
chemistri
detect
technolog
suitabl
nucleic
acid
amplif
test
naat
evalu
deploy
diagnost
laboratori
technolog
direct
detect
nucleic
acid
suitabl
diagnost
applic
molecular
diagnost
test
use
technolog
polymeras
chain
reaction
pcr
nucleic
acid
amplif
nasba
strand
displac
amplif
sda
consid
fact
microorgan
rna
dna
genom
implic
rti
pcr
becom
wide
deploy
chemistri
use
amplifi
genet
materi
varieti
respiratori
pathogen
pathogen
rna
genom
pcr
reaction
must
preced
revers
transcript
rt
reaction
convert
rna
complementari
dna
cdna
amplificationdetect
reaction
modifi
variou
way
depend
assay
develop
need
diagnost
employ
pcr
fall
one
two
broad
categori
q
pcr
pcr
due
quantit
natur
qpcr
suitabl
applic
requir
assess
pathogen
level
typic
case
assay
aid
diagnosi
rti
one
featur
qpcr
well
suit
detect
respiratori
virus
step
assay
take
place
close
system
featur
limit
potenti
carryov
contamin
thu
potenti
inaccur
result
detect
singl
analyt
achiev
rel
eas
detect
multipl
analyt
multiplex
via
qpcr
requir
varieti
workflow
manipul
due
limit
inher
detect
platform
use
chemistri
assay
incorpor
pcr
gener
greater
multiplex
capac
incorpor
qpcr
need
test
panel
respiratori
virus
aid
diagnosi
rti
emerg
fact
multipl
etiolog
agent
present
overlap
clinic
sign
symptom
multiplex
strategi
employ
pcr
chemistri
well
suit
rti
diagnosi
particularli
consid
fact
mani
recent
discov
respiratori
virus
proven
difficult
detect
tradit
method
advanc
amplif
system
array
greatli
improv
diagnost
yield
clinic
algorithm
last
decad
migrat
toward
multiplex
detect
strategi
respiratori
virus
led
signific
improv
detect
rate
nonetheless
multiplex
strategi
inher
limit
instanc
attempt
expand
diagnost
capac
test
introduct
multipl
primer
probe
set
target
differ
viral
genom
met
varieti
technic
logist
challeng
neg
affect
cost
accuraci
test
certain
point
simplic
afford
featur
qpcr
outweigh
adapt
requir
increas
multiplex
capac
sever
detect
platform
accommod
multiplex
applic
reach
diagnost
laboratori
recent
year
advantag
disadvantag
term
abil
help
laboratori
achiev
goal
etiolog
diagnosi
rti
laboratori
continu
evalu
emerg
technolog
consider
relat
cost
accuraci
diagnosi
remain
forefront
two
signific
advanc
multiplex
enabl
accur
reproduc
flexibl
analyt
detect
involv
technolog
patent
luminex
corpor
http
wwwluminexcorpcom
first
innov
array
compos
spectral
distinct
microspher
bead
known
detect
earli
report
technolog
support
potenti
inclus
system
design
protein
nucleic
acid
detect
sinc
numer
research
diagnost
applic
incorpor
xmap
detect
three
platform
util
technolog
commerci
avail
one
abil
simultan
detect
analyt
singl
sampl
ie
reaction
well
microtit
plate
second
expand
multiplex
capabl
analyt
per
reaction
well
latest
platform
commerci
demonstr
improv
eas
use
applic
design
simultan
detect
analyt
singl
reaction
well
second
signific
advanc
array
initi
report
patent
innov
involv
univers
minim
complementari
oligonucleotid
sequenc
tag
antitag
tag
antitag
design
maxim
ratio
observ
detect
step
nucleic
acid
applic
fig
advantag
univers
array
hybrid
optim
requir
optim
tagantitag
hybrid
condit
appli
nucleic
applic
particularli
noteworthi
consid
potenti
nonspecif
interact
multiplex
reaction
mixtur
univers
array
sort
coupl
xmap
detect
enzymat
step
requir
detect
identif
analyt
occur
solut
phase
kinet
advantag
compar
array
key
factor
underli
superior
perform
applic
incorpor
two
innov
univers
array
commerci
avail
luminex
corpor
also
foundat
xtag
applic
commerci
luminex
molecular
diagnost
advantag
nucleic
test
incorpor
xmap
xtag
technolog
numer
priori
test
signific
multiplex
capac
achiev
qpcr
chemistri
current
use
diagnost
applic
furthermor
neglig
among
tag
antitag
specif
pair
elev
baselin
diagnost
sensit
specif
consequ
simplifi
optim
effort
assay
develop
process
luminex
technolog
extens
adopt
research
diagnost
applic
comprehens
assess
author
us
center
diseas
control
prevent
cdc
us
food
drug
administr
fda
end
xtag
rvp
commerci
european
union
diagnost
kit
use
xmap
detect
earli
us
canadian
version
vitro
diagnost
ivd
devic
receiv
regulatori
clearanc
fda
health
canada
respect
kit
provid
comprehens
viral
coverag
xtag
rvp
ivd
product
line
abil
simultan
detect
follow
virus
influenza
flu
subtyp
flu
flu
subtyp
flu
flu
pathogen
avian
influenza
flu
syncyti
viru
rsv
para
cov
metapneumoviru
hmpv
adeno
entero
rhino
test
provid
uniqu
result
virus
list
singl
result
provid
close
relat
member
picornavirida
famili
enteroviru
rhinoviru
due
high
degre
nucleic
acid
sequenc
homolog
across
differ
strain
virus
addit
detect
aforement
virus
singl
reaction
well
two
uniqu
result
gener
control
detect
multiplex
reaction
first
escherichia
coli
phage
intern
control
ad
patient
sampl
intern
control
monitor
step
assay
nucleic
acid
extract
rt
multiplex
pcr
multiplex
target
specif
primer
extens
tspe
univers
array
sort
xmap
detect
second
bacteriophag
lambda
assay
separ
well
control
subset
step
pcr
tspe
sort
detect
assess
result
two
control
togeth
result
target
analyt
abl
ascertain
whether
assay
failur
due
failur
nucleic
acid
extractionrt
step
subsequ
assay
step
pcrtspesortingdetect
diagnost
sensit
specif
kit
establish
evalu
prospect
retrospect
collect
clinic
sampl
demograph
featur
studi
cohort
summar
tabl
worthwhil
note
sever
patient
present
varieti
coinfect
detect
xtag
rvp
would
otherwis
miss
tradit
method
patient
sampl
prospect
collect
nasopharyng
np
swab
use
establish
clinic
perform
characterist
us
version
kit
tabl
ivd
xtag
rvp
fast
introduc
europ
canada
late
line
extens
streamlin
workflow
shorter
time
result
modifi
analyt
coverag
compar
xtag
rvp
addit
perform
valid
requir
regulatori
applic
numer
valid
xtag
rvp
product
line
sever
involv
comparison
applic
support
conclus
improv
diagnost
coverag
afford
xtagxmap
detect
introduct
respiratori
viral
panel
built
xtagxmap
technolog
serv
catalyst
naat
adopt
diagnost
algorithm
unit
state
januari
clearanc
xtag
rvp
fda
repres
first
clearanc
respiratori
viral
panel
util
nucleic
detect
devic
also
first
receiv
fda
clearanc
recent
discov
respiratori
viru
hmpv
flu
subtyp
abil
specif
identifi
season
subtyp
influenza
prove
invalu
tool
novel
influenza
pandem
ensu
follow
year
three
known
type
influenza
influenza
b
c
influenza
virus
classifi
subtyp
base
two
main
surfac
glycoprotein
hemagglutinin
neuraminidas
http
wwwcdcgovfluaviangeninfofluviruseshtm
observ
date
suggest
influenza
b
continu
evolv
antigen
drift
influenza
evolv
antigen
shift
http
wwwcdcgovfluaviangeninfofluviruseshtm
antigen
drift
gradual
process
chang
via
point
mutat
lead
novel
strain
virus
explain
peopl
anim
infect
viru
type
eg
influenza
b
name
host
respons
infect
strain
may
grant
immun
new
strain
emerg
antigen
drift
http
wwwcdcgovfluaviangeninfofluviruseshtm
antigen
shift
hand
dramat
process
result
genet
reassort
occur
influenza
virus
exchang
genet
materi
abrupt
process
occur
two
influenza
virus
infect
singl
human
anim
host
http
antigen
shift
lead
global
influenza
pandem
three
condit
met
new
influenza
subtyp
introduc
human
popul
viru
caus
seriou
ill
human
viru
easili
spread
person
person
sustain
manner
http
wwwcdcgovfluaviangeninfofluviruseshtm
exactli
happen
novel
influenza
subtyp
emerg
mexico
spring
key
innov
design
xtag
rvp
prove
invalu
pandem
manner
detect
influenza
specif
multiplex
test
simultan
probe
region
influenza
matrix
gene
conserv
across
influenza
subtyp
togeth
subtyp
specif
region
variabl
hemagglutinin
gene
accordingli
influenza
viru
recogn
probe
xtag
rvp
gener
flu
result
featur
test
address
label
clear
regulatori
agenc
prior
emerg
influenza
earli
day
pandem
cluster
case
present
new
york
citi
metropolitan
area
avail
xtag
rvp
affect
hospit
key
element
surg
respons
specif
sever
diagnost
test
option
evalu
initi
outbreak
xtag
rvp
prove
best
tool
avail
emerg
pandem
time
fda
sanction
test
specif
identif
novel
influenza
one
develop
cdc
made
avail
feder
emerg
use
author
sampl
collect
initi
new
york
citi
outbreak
confirm
posit
novel
influenza
new
york
state
depart
health
gener
flu
result
xtag
rvp
word
xtag
rvp
enabl
clinician
rapidli
discrimin
infect
caus
novel
influenza
strain
caus
season
strain
influenza
virus
includ
panel
clinic
util
xtag
rvp
pandem
limit
abil
detect
influenza
note
fact
virus
overlap
clinic
featur
circul
time
simultan
probe
multipl
virus
singl
patient
sampl
xtag
rvp
proven
solut
laboratori
diagnosi
rti
multiplex
detect
panel
respiratori
virus
also
afford
advantag
hospit
surveil
program
aim
limit
nosocomi
infect
clinic
condit
asthma
bronchiol
benefit
avail
multiplex
respiratori
viral
panel
particularli
light
emerg
evid
implic
one
viru
condit
consid
respiratori
syncyti
viru
well
establish
key
risk
factor
bronchiol
infant
abil
discrimin
virus
may
caus
agent
eg
rhinoviru
key
element
clinic
algorithm
furthermor
dual
infect
note
bronchiol
one
studi
demonstr
higher
clinic
sever
score
prolong
hospit
stay
patient
infect
one
viru
light
differ
treatment
cours
avail
physician
aforement
clinic
condit
accur
laboratori
diagnosi
prove
vital
condit
asthma
bronchiol
known
involv
respiratori
virus
mechan
agent
affect
patient
statu
still
investig
impact
respiratori
virus
immunocompromis
patient
patient
pneumonia
also
area
investig
studi
need
fulli
elucid
role
respiratori
virus
condit
evalu
sure
benefit
avail
panel
xtag
rvp
xtag
rvp
fast
similarli
studi
efficaci
novel
vaccin
one
develop
rhinoviru
benefit
avail
respiratori
viral
panel
addit
diagnost
clinic
research
applic
highlight
multiplex
respiratori
viral
panel
tremend
util
surveil
program
prevent
therapeut
strategi
emerg
epidemiolog
inform
gather
program
augment
extens
data
afford
multiplex
panel
past
two
decad
etiolog
diagnosi
rti
proven
import
element
clinic
algorithm
time
accur
data
multitud
pathogen
implic
rti
associ
clinic
condit
paramount
tradit
method
cell
cultur
still
role
play
diagnost
algorithm
howev
advanc
nucleic
acid
amplif
technolog
led
increas
adopt
clinic
laboratori
innov
link
pcr
particularli
noteworthi
innov
underli
xtag
rvp
exampl
advanc
technolog
translat
clinic
util
correspond
author
coauthor
employ
luminex
molecular
diagnost
inc
wholli
own
subsidiari
luminex
corpor
